TABLE 2.
Treatment Duration Between Prucalopride, Lubiprostone, Linaclotide, and Plecanatide During the Follow-Up Period
| Persistence of index treatment a,b | Prucalopride(n = 675) | Lubiprostone(n = 1,591) | Linaclotide(n = 11,105) | Plecanatide(n = 1,329) | All patients(N = 14,700) |
|---|---|---|---|---|---|
| Treatment duration, days | |||||
| Mean (SD) | 123.44 (109.42) | 100.79 (101.46) | 117.18 (106.37) | 112.25 (100.26) | 115.25 (105.58) |
| Median (range) | 90.0 (5.0-457.0) | 60.0 (1.0-455.0) | 89.0 (1.0-457.0) | 90.0 (10.0-457.0) | 84.0 (1.0-457.0) |
| Pairwise P valuea,c | — | <0.001 | 0.300 | 0.213 | — |
| Treatment duration category, days, n (%) | |||||
| 0-30 | 233 (34.5) | 718 (45.1) | 3,772 (34.0) | 440 (33.1) | 5,163 (35.1) |
| 31-60 | 53 (7.9) | 136 (8.5) | 963 (8.7) | 93 (7.0) | 1,245 (8.5) |
| 61-90 | 89 (13.2) | 210 (13.2) | 2,013 (18.1) | 321 (24.2) | 2,633 (17.9) |
| 91-180 | 126 (18.7) | 224 (14.1) | 1,863 (16.8) | 211 (15.9) | 2,424 (16.5) |
| 181-270 | 81 (12.0) | 154 (9.7) | 1,200 (10.8) | 126 (9.5) | 1,561 (10.6) |
| ≥271 | 93 (13.8) | 149 (9.4) | 1,294 (11.7) | 138 (10.4) | 1,674 (11.4) |
| Pairwise P valuec | — | <0.001 | <0.05 | <0.001 | — |
a Differences across treatment groups may reflect differences in the length of the follow-up period.
b Accounting for stockpiling, any days of supply that fell outside of the follow-up period were excluded.
c Pairwise statistical comparisons between prucalopride and each of the 3 comparator treatment cohorts were conducted using Wilcoxon rank-sum tests for continuous variables and chi-square tests for binary variables. Comparisons were conducted only if the P value for the joint statistical comparison was significant (P < 0.05).